Percutaneous coronary intervention (PCI) has become the most common form of coronary
revascularization worldwide. Although PCI is a safe procedure, it may have multiple risks
including bleeding, coronary dissection, abrupt vessel closure, and myocardial necrosis. It
is estimated that approximately 25% of patients undergoing PCI have significant
postprocedural creatinine kinase (CK)/creatinine kinase myocardial band (CK-MB) elevations
and approximately 50% of patients have significant post-procedural troponin elevations.
Initially, it was felt these elevations were simple enzyme leaks with no long-term
Now, several studies have demonstrated that periprocedural infarction is associated with
short-, intermediate-, and long-term adverse outcomes, most notably mortality. Pretreatment
with antiplatelets such as aspirin and clopidogrel play an important role in reducing
cardiovascular events (CV events) following PCI.
Omega -3 polyunsaturated fatty acids (PUFAs) have antiplatelet effect. It may also improve
response to aspirin and clopidogrel in low-response patients.
This study is a randomized clinical trial (RCT) evaluating the effect of omega 3 supplement
[with 400mg Eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA)] on short-term
(within 30 days) and long-term (after one year) major adverse cardiac events (MACE) in
patients undergoing elective PCI. Eighty patients planed to do elective PCI will be
categorized into two groups. The first group will be received standard regimen for PCI
(aspirin, clopidogrel, and heparin) and the second group will be treated with standard
regimen in addition to 3 gram omega 3 (12 hours before PCI). The main end point of the trial
was short-term (within 30-days) and long-term (after one year) incidence of MACE (death,
myocardial infarction, or unplanned revascularization).